Healthcare | |
Sclerostin Modulation Holds Promise for Dental Indications | |
AbbasR. Zaher1  JuanMartin Palomo2  Leena Palomo3  MohamedG. Hassan4  | |
[1] Department of Orthodontics, Faculty of Dentistry, Alexandria University, Alexandria 21526, Egypt;Department of Orthodontics, School of Dental Medicine, Case Western Reserve University, Cleveland, OH 44106-4905, USA;Department of Periodontics, School of Dental Medicine, Case Western Reserve University, Cleveland, OH 44106-4905, USA;Division of Craniofacial Anomalies, Department of Orofacial Sciences, University of California San Francisco, San Francisco, CA 94143, USA; | |
关键词: sclerostin; anti-sclerostin; bone remodeling; alveolar bone; orthodontic; tooth movement; periodontitis; bone loss; | |
DOI : 10.3390/healthcare6040134 | |
来源: DOAJ |
【 摘 要 】
Sclerostin modulation is a novel therapeutic bone regulation strategy. The anti-sclerostin drugs, proposed in medicine for skeletal bone loss may be developed for jaw bone indications in dentistry. Alveolar bone responsible for housing dentition share common bone remodeling mechanisms with skeletal bone. Manipulating alveolar bone turnover can be used as a strategy to treat diseases such as periodontitis, where large bone defects from disease are a surgical treatment challenge and to control tooth position in orthodontic treatment, where moving teeth through bone in the treatment goal. Developing such therapeutics for dentistry is a future line for research and therapy. Furthermore, it underscores the interprofessional relationship that is the future of healthcare.
【 授权许可】
Unknown